A Tension-Based Model Distinguishes Hypertrophic versus Dilated Cardiomyopathy

Cell

Volumn 165, Issue 5, 2016, Pages 1147-1159

  Davis, Jennifer ^a   Davis, L Craig ^b   Correll, Robert N ^c   Makarewich, Catherine A ^d   Schwanekamp, Jennifer A ^c   Moussavi Harami, Farid ^a   Wang, Dan ^a   York, Allen J ^c   Wu, Haodi ^e   Houser, Steven R ^d   Seidman, Christine E ^f   Seidman, Jonathan G ^f   Regnier, Michael ^a   Metzger, Joseph M ^g   Wu, Joseph C ^e   Molkentin, Jeffery D ^c,h  

^a University of Washington   (United States)

^b 10244 Normandy Dr ^*  (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

^d TEMPLE UNIVERSITY   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^h HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTININ; CALCINEURIN; CALCIUM; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TROPOMYOSIN; TROPONIN C; MITOGEN ACTIVATED PROTEIN KINASE; MUSCLE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CARDIAC MUSCLE CELL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; GENE MUTATION; HEART DEVELOPMENT; HYPERTROPHIC CARDIOMYOPATHY; INDUCED PLURIPOTENT STEM CELL; MOUSE; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; TENSION; ANIMAL; AORTA; DISEASE MODEL; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENETICS; METABOLISM; MUSCLE FIBRIL; MUTATION; PATHOLOGY;

ANIMALS; AORTA; CALCINEURIN; CALCIUM; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INDUCED PLURIPOTENT STEM CELLS; MICE; MUSCLE PROTEINS; MUTATION; MYOFIBRILS;

EID: 84963984775     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2016.04.002     Document Type: Article

References (36)

1. D.M. Bers Cardiac excitation-contraction coupling Nature 415 2002 198 205
2. O.F. Bueno, L.J. De Windt, K.M. Tymitz, S.A. Witt, T.R. Kimball, R. Klevitsky, T.E. Hewett, S.P. Jones, D.J. Lefer, C.F. Peng, and et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice EMBO J. 19 2000 6341 6350
3. J. Davis, and J.M. Metzger Combinatorial effects of double cardiomyopathy mutant alleles in rodent myocytes: a predictive cellular model of myofilament dysregulation in disease PLoS ONE 5 2010 e9140
4. J. Davis, H. Wen, T. Edwards, and J.M. Metzger Thin filament disinhibition by restrictive cardiomyopathy mutant R193H troponin I induces Ca2+-independent mechanical tone and acute myocyte remodeling Circ. Res. 100 2007 1494 1502
5. J. Davis, H. Wen, T. Edwards, and J.M. Metzger Allele and species dependent contractile defects by restrictive and hypertrophic cardiomyopathy-linked troponin I mutants J. Mol. Cell. Cardiol. 44 2008 891 904
6. J. Davis, S. Yasuda, N.J. Palpant, J. Martindale, T. Stevenson, K. Converso, and J.M. Metzger Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy J. Mol. Cell. Cardiol. 53 2012 446 457
7. D. Fatkin, and R.M. Graham Molecular mechanisms of inherited cardiomyopathies Physiol. Rev. 82 2002 945 980
8. D. Fatkin, B.K. McConnell, J.O. Mudd, C. Semsarian, I.G. Moskowitz, F.J. Schoen, M. Giewat, C.E. Seidman, and J.G. Seidman An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy J. Clin. Invest. 106 2000 1351 1359
9. E.R. Feest, F. Steven Korte, A.Y. Tu, J. Dai, M.V. Razumova, C.E. Murry, and M. Regnier Thin filament incorporation of an engineered cardiac troponin C variant (L48Q) enhances contractility in intact cardiomyocytes from healthy and infarcted hearts J. Mol. Cell. Cardiol. 72 2014 219 227
10. A.A. Geisterfer-Lowrance, M. Christe, D.A. Conner, J.S. Ingwall, F.J. Schoen, C.E. Seidman, and J.G. Seidman A mouse model of familial hypertrophic cardiomyopathy Science 272 1996 731 734
11. A.M. Gordon, E. Homsher, and M. Regnier Regulation of contraction in striated muscle Physiol. Rev. 80 2000 853 924
12. M. Hamada, S. Ikeda, and Y. Shigematsu Advances in medical treatment of hypertrophic cardiomyopathy J. Cardiol. 64 2014 1 10
13. J.T. Hinson, A. Chopra, N. Nafissi, W.J. Polacheck, C.C. Benson, S. Swist, J. Gorham, L. Yang, S. Schafer, C.C. Sheng, and et al. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy Science 349 2015 982 986
14. S.R. Houser, and J.D. Molkentin Does contractile Ca2+ control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci. Signal. 1 2008 pe31
15. A.F. Huxley Muscle structure and theories of contraction Prog. Biophys. Biophys. Chem. 7 1957 255 318
16. A. Kalyva, F.I. Parthenakis, M.E. Marketou, J.E. Kontaraki, and P.E. Vardas Biochemical characterisation of Troponin C mutations causing hypertrophic and dilated cardiomyopathies J. Muscle Res. Cell Motil. 35 2014 161 178
17. I. Kehat, and J.D. Molkentin Molecular pathways underlying cardiac remodeling during pathophysiological stimulation Circulation 122 2010 2727 2735
18. I. Kehat, J. Davis, M. Tiburcy, F. Accornero, M.K. Saba-El-Leil, M. Maillet, A.J. York, J.N. Lorenz, W.H. Zimmermann, S. Meloche, and J.D. Molkentin Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth Circ. Res. 108 2011 176 183
19. K.L. Kreutziger, N. Piroddi, J.T. McMichael, C. Tesi, C. Poggesi, and M. Regnier Calcium binding kinetics of troponin C strongly modulate cooperative activation and tension kinetics in cardiac muscle J. Mol. Cell. Cardiol. 50 2011 165 174
20. F. Lan, A.S. Lee, P. Liang, V. Sanchez-Freire, P.K. Nguyen, L. Wang, L. Han, M. Yen, Y. Wang, N. Sun, and et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells Cell Stem Cell 12 2013 101 113
21. M.M. LeWinter, and H.L. Granzier Titin is a major human disease gene Circulation 127 2013 938 944
22. S.W. Luckey, L.A. Walker, T. Smyth, J. Mansoori, A. Messmer-Kratzsch, A. Rosenzweig, E.N. Olson, and L.A. Leinwand The role of Akt/GSK-3beta signaling in familial hypertrophic cardiomyopathy J. Mol. Cell. Cardiol. 46 2009 739 747
23. 2+ channel antagonist inhibits hypertrophic signaling without reducing cardiac contractility Circ. Res. 110 2012 669 674
24. E.M. McNally, J.R. Golbus, and M.J. Puckelwartz Genetic mutations and mechanisms in dilated cardiomyopathy J. Clin. Invest. 123 2013 19 26
25. J.M. Metzger, and M.V. Westfall Covalent and noncovalent modification of thin filament action: the essential role of troponin in cardiac muscle regulation Circ. Res. 94 2004 146 158
26. D.E. Michele, C.A. Gomez, K.E. Hong, M.V. Westfall, and J.M. Metzger Cardiac dysfunction in hypertrophic cardiomyopathy mutant tropomyosin mice is transgene-dependent, hypertrophy-independent, and improved by beta-blockade Circ. Res. 91 2002 255 262
27. J. Mogensen, T. Kubo, M. Duque, W. Uribe, A. Shaw, R. Murphy, J.R. Gimeno, P. Elliott, and W.J. McKenna Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations J. Clin. Invest. 111 2003 209 216
28. J.A. Negroni, and E.C. Lascano Simulation of steady state and transient cardiac muscle response experiments with a Huxley-based contraction model J. Mol. Cell. Cardiol. 45 2008 300 312
29. I. Ostman-Smith Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death Fundam. Clin. Pharmacol. 24 2010 637 652
30. M.S. Parvatiyar, J.R. Pinto, J. Liang, and J.D. Potter Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C J. Biol. Chem. 285 2010 27785 27797
31. V. Shettigar, B. Zhang, S.C. Little, H.E. Salhi, B.J. Hansen, N. Li, J. Zhang, S.R. Roof, H.T. Ho, L. Brunello, and et al. Rationally engineered Troponin C modulates in vivo cardiac function and performance in health and disease Nat. Commun. 7 2016 10794
32. R. Spoladore, M.S. Maron, R. D'Amato, P.G. Camici, and I. Olivotto Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence Eur. Heart J. 33 2012 1724 1733
33. N. Sun, M. Yazawa, J. Liu, L. Han, V. Sanchez-Freire, O.J. Abilez, E.G. Navarrete, S. Hu, L. Wang, A. Lee, and et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy Sci. Transl. Med. 4 2012 130ra47
34. J.C. Tardiff, L. Carrier, D.M. Bers, C. Poggesi, C. Ferrantini, R. Coppini, L.S. Maier, H. Ashrafian, S. Huke, and J. van der Velden Targets for therapy in sarcomeric cardiomyopathies Cardiovasc. Res. 105 2015 457 470
35. S.B. Tikunova, and J.P. Davis Designing calcium-sensitizing mutations in the regulatory domain of cardiac troponin C J. Biol. Chem. 279 2004 35341 35352
36. D. Wang, I.M. Robertson, M.X. Li, M.E. McCully, M.L. Crane, Z. Luo, A.Y. Tu, V. Daggett, B.D. Sykes, and M. Regnier Structural and functional consequences of the cardiac troponin C L48Q Ca(2+)-sensitizing mutation Biochemistry 51 2012 4473 4487